Citations

Clear

2117 citation(s) found for "Mayo, Steven".

P1‐458: Differential association of memory endophenotypes to APOE alleles
Pedraza, Otto , Allen, Mariet , Ivnik, Robert J., Graff‐Radford, Neill R. , Roberts, Rosebud O., Petersen, Ronald C. , Younkin, Steven G., Ertekin‐Taner, Nilüfer , Crook, Julia E. , Smith, Glenn E. , Knopman, David S. , Pankratz, V. Shane

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2011.05.740 Get It

S1‐01‐02: Genome‐wide association studies using prospective cohorts: The CHARGE consortium
Fitzpatrick, Annette L., Younkin, Steven G., Wolf, Philip A. , Carrasquillo, Minerva M., DeStefano, Anita L. , Seshadri, Sudha , Ikram, M. Arfan , Guðnason, Vilmundur , Boada, Merçé , Williams, Julie , Amouyel, Philippe , Launer, Lenore J. , López, Oscar L. , Duijn, Cornelia M. van , Breteler, Monique M.B. , Lambert, Jean‐Charles , Harold, Denise , Ruiz, Agustı́n

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2011.05.199 Get It

Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma
Yang, Zhi‐Zhang, Grote, Deanna M., Ziesmer, Steven C., Novak, Anne J. , Ansell, Stephen M. , Manske, Michelle K. , Witzig, Thomas E.

Mayo Clinic

Blood | July 1, 2011 | Volume: 118 | Issue: 10 | Pages: 2809-2820

10.1182/blood-2011-03-340885 | PMID 21719603 Get It

AbstractElevated serum levels of the soluble form of IL-2 receptor α (sIL-2Rα) have been correlated with a poor prognosis in a variety of different types of cancers. However, its biologic relevance remains unclear and controversial. In patients with follicular B-cell non-Hodgkin lymphoma (FL), we observed that serum sIL-2Rα levels were elevated compared with controls and that elevated sIL-2Rα levels before treatment were associated with a poor outcome. To explore the mechanism by which sIL-2Rα may contribute to a poor prognosis in FL, we determined the effects of sIL-2Rα on IL-2 signaling and found that the sIL-2Rα–IL-2 complex promoted T-cell differentiation toward to inhibitory Treg cells rather than TH1 or TH17 cells. Shed by activated T cells that express membrane-bound IL-2Rα, sIL-2Rα further enhanced IL-2–mediated phosphorylation of Stat5 thereby significantly up-regulating Foxp3 expression in CD4+ T cells. We found that CD4+ T cells treated with either IL-2 or sIL-2Rα–IL-2 complex, but not with sIL-2Rα alone, inhibited the function of CD8+ T cells. Taken together, these results indicate that sIL-2Rα actually plays an active biologic role in FL by binding IL-2 and promoting IL-2 signaling rather than depleting IL-2 and blocking its function.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Lacy, Martha Q. , Allred, Jacob B., Hayman, Suzanne R. , Short, Kristen Detweiler, Dispenzieri, Angela , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Dingli, David , Zeldenrust, Steven R., Fonseca, Rafaël , Bergsagel, P. Leif , Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J. , Reeder, Craig B. , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Roy, Vivek , Mıkhael, Joseph , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | June 20, 2011 | Volume: 118 | Issue: 11 | Pages: 2970-2975

10.1182/blood-2011-04-348896 | PMID 21690557 Get It

Abstract Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 or 4 mg daily with dexamethasone 40 mg weekly. Thirty-five patients were enrolled in each cohort. Confirmed responses in the 2-mg cohort consisted of very good partial response (VGPR) in 5 (14%), partial response (PR) in 4 (11%), minor response (MR) in 8 (23%) for an overall response rate of 49%. In the 4-mg cohort, confirmed responses consisted of complete response (CR) in 1 (3%), VGPR in 3 (9%), PR in 6 (17%), MR in 5 (14%) for an overall response rate of 43%. Overall survival at 6 months is 78% and 67% in the 2- and 4-mg cohort, respectively. Myelosuppression was the most common toxicity. This nonrandomized data suggests no advantage for 4 mg over the 2 mg daily. Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896.
Laparoscopic Intraoperative Biliary Ultrasonography: Findings During Laparoscopic Cholecystectomy for Acute Disease
Pfluke, Jason M., Bowers, Steven P.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | June 15, 2011 | Volume: 21 | Issue: 6 | Pages: 505-509

10.1089/lap.2010.0280 | PMID 21675861 Get It

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Madan, Sumit , Lacy, Martha Q. , Dispenzieri, Angela , Hayman, Suzanne R. , Detweiler‐Short, Kristen, Dingli, David , Zeldenrust, Steven R., Lust, John A., Greipp, Philip R., Rajkumar, S. Vincent , Kumar, Shaji , Gertz, Morie A. , Buadi, Francis K. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 7 | Pages: 1763-1765

10.1182/blood-2011-04-350009 | PMID 21673347 Get It

AbstractThe efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.
Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009
Eggleston, Karen , Shah, Nilay D., Smith, Steven A., Berndt, Ernst R. , Newhouse, Joseph P.

Mayo Clinic

American Economic Review | June 1, 2011 | Volume: 101 | Issue: 3 | Pages: 206-211

10.1257/aer.101.3.206 | PMID 29517880 Get It

Although US health care expenditures reached 17.6 percent of GDP in 2009, quality measurement in this important service sector remains limited. Studying quality changes associated with 11 years of health care for patients with diabetes, we find that the value of reduced mortality and avoided treatment spending, net of the increase in annual spending, was $9,094 for the average patient. These results suggest that the unit cost of diabetes treatment, adjusting for the value of health outcomes, has been roughly constant. Since input prices have not been declining, our results are consistent with productivity improvement in health care.
1722 ASSOCIATIONS BETWEEN MODEST WEIGHT LOSS AND ONSET AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS
Sarma, Aruna V. , Hollingsworth, John M. , Jacobson, Debra J., McGree, Michaela E. , Dunn, Rodney L. , Lieber, Michael M., Jacobsen, Steven J. , Sauver, Jennifer L. St.

Mayo Clinic

Journal of Urology | May 20, 2011 | Volume: 185 | Issue: 4S | Pages: No page available

10.1016/j.juro.2011.02.1993 Get It